About
BTG plc was a global healthcare company specializing in innovative products for interventional medicine. The company focused on developing therapies for critical care, cancer, and vascular diseases, utilizing minimally invasive techniques to enhance patient outcomes. BTG's portfolio included products for interventional oncology, such as TheraSphere™ and the GALIL™ cryoablation system, as well as the EKOS™ Endovascular System for vascular treatments. Additionally, it offered specialty pharmaceuticals like DigiFab® and Voraxaze®. Founded in the early 1980s from the merger of two British government bodies, BTG was privatized in 1992 and went public in 1995. The company operated globally, serving healthcare providers, including hospitals and clinics, and its products were utilized by specialists in interventional radiology, oncology, and vascular care. In 2019, BTG was acquired by Boston Scientific, integrating its innovative offerings into their interventional medicine divisions.
Keywords
Company Information
-
Employees 590
-
Founded 1948
Location
300 Boston Scientific Way, Marlborough, Massachusetts, United States, 01752
